|
1
|
Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.
|
J Infect Dis
|
2007
|
1.88
|
|
2
|
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
|
Cancer Chemother Pharmacol
|
2009
|
1.47
|
|
3
|
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
|
Anticancer Drugs
|
2009
|
1.26
|
|
4
|
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
|
Clin Genitourin Cancer
|
2007
|
1.23
|
|
5
|
Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles.
|
Hum Immunol
|
2003
|
1.20
|
|
6
|
Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
|
Blood
|
2009
|
1.14
|
|
7
|
CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
|
J Immunol
|
2003
|
1.12
|
|
8
|
A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
|
J Virol
|
2012
|
1.09
|
|
9
|
Evidence for X-chromosomal schizophrenia associated with microRNA alterations.
|
PLoS One
|
2009
|
1.08
|
|
10
|
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
|
Clin Cancer Res
|
2005
|
1.07
|
|
11
|
Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease.
|
J Infect Dis
|
2008
|
1.06
|
|
12
|
Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
|
J Virol
|
2004
|
1.05
|
|
13
|
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
|
J Infect Dis
|
2012
|
1.03
|
|
14
|
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
|
Clin Cancer Res
|
2003
|
1.02
|
|
15
|
Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion.
|
Hum Immunol
|
2004
|
0.99
|
|
16
|
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
|
Clin Lung Cancer
|
2004
|
0.99
|
|
17
|
Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.
|
J Infect Dis
|
2006
|
0.98
|
|
18
|
Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy.
|
J Clin Oncol
|
2005
|
0.98
|
|
19
|
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
|
J Thorac Oncol
|
2006
|
0.97
|
|
20
|
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
|
Cancer
|
2004
|
0.96
|
|
21
|
In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
|
Exp Hematol
|
2006
|
0.95
|
|
22
|
Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
|
Biol Blood Marrow Transplant
|
2005
|
0.94
|
|
23
|
Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge.
|
J Immunol
|
2003
|
0.94
|
|
24
|
Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.
|
Blood
|
2004
|
0.93
|
|
25
|
Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients.
|
J Infect Dis
|
2005
|
0.92
|
|
26
|
Identification of high risk DISC1 protein structural variants in patients with bipolar spectrum disorder.
|
Neurosci Lett
|
2010
|
0.90
|
|
27
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
Clin Cancer Res
|
2006
|
0.90
|
|
28
|
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
|
Clin Cancer Res
|
2004
|
0.90
|
|
29
|
Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
|
Cancer Res
|
2004
|
0.89
|
|
30
|
Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition.
|
Vaccine
|
2005
|
0.86
|
|
31
|
Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
|
Blood
|
2011
|
0.84
|
|
32
|
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
|
Cancer Chemother Pharmacol
|
2011
|
0.84
|
|
33
|
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
|
Clin Lung Cancer
|
2011
|
0.82
|
|
34
|
Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity.
|
J Infect Dis
|
2003
|
0.81
|
|
35
|
Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
|
Transpl Int
|
2011
|
0.81
|
|
36
|
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
|
Int J Clin Oncol
|
2011
|
0.79
|
|
37
|
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
|
Clin Lung Cancer
|
2004
|
0.77
|
|
38
|
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
|
Clin Cancer Res
|
2003
|
0.77
|
|
39
|
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
|
Cancer Chemother Pharmacol
|
2004
|
0.76
|
|
40
|
Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients.
|
Transplantation
|
2016
|
0.75
|
|
41
|
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
|
Cancer Chemother Pharmacol
|
2002
|
0.75
|